低分化甲状腺癌侵袭范围对预后意义的研究
该研究回顾性分析47例符合2017年WHO标准的低分化甲状腺癌(PDTC)患者,按侵袭范围分组。结果显示,仅包膜侵犯或局灶血管侵犯者预后极佳,而广泛侵袭者预后差,5年无病生存率分别为100%、73%和17%(p=0.0016)。
要点
- 侵袭范围是PDTC的重要预后因素。
- 仅包膜侵犯或局灶血管侵犯者预后极佳。
- 广泛侵袭者5年无病生存率仅17%。
核心结论
- 侵袭范围影响PDTC患者临床结局。
- 仅包膜侵犯或局灶血管侵犯者预后极佳。
研究设计与样本
- 回顾性识别2005-2018年连续诊断的47例PDTC手术病例。
- 所有病例经复核符合2017年WHO内分泌器官肿瘤分类PDTC标准。
- 按侵袭范围分为四组:仅包膜侵犯、局灶血管侵犯(少于4灶)、广泛血管侵犯(4灶或以上)、广泛侵袭。
主要发现
- 47例中女性28例(60%),男性19例(40%),诊断时平均年龄57岁,平均肿瘤大小4.3cm。
- 平均核分裂数8个/10高倍视野(范围1-34),21例(45%)存在坏死。
- 8例(17%)仅包膜侵犯,5例(11%)局灶血管侵犯,18例(38%)广泛血管侵犯,16例(34%)广泛侵袭。
- 42例(89%)有随访数据:7例(17%)死于疾病(平均生存时间6.4年),11例(26%)有远处转移,24例(57%)无疾病证据(平均随访5.6年)。
- 诊断时8例(19%)为M1疾病;M0患者5年无病生存率:仅包膜侵犯或局灶血管侵犯(n=7)为100%,广泛血管侵犯(n=11)为73%,广泛侵袭(n=6)为17%,Kaplan-Meier分析组间差异显著(p=0.0016)。
临床怎么用
- 病理报告应详细描述PDTC的侵袭范围以助预后分层。
- 对仅包膜侵犯或局灶血管侵犯的PDTC患者可考虑更保守的随访策略。
局限性
- 回顾性研究,样本量较小(47例)。
- 随访数据不完整(仅42例有随访)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: The 2017 World Health Organization (WHO) Classification of Tumors of Endocrine Organs defines poorly differentiated thyroid carcinoma (PDTC) as a tumor with conventional criteria of malignancy (capsular penetration or vascular invasion) with solid, insular, or trabecular growth, a lack of nuclear features of papillary thyroid carcinoma, and increased mitotic activity, tumor necrosis, or convoluted nuclei. The extent of invasion has been shown to be prognostic in follicular thyroid carcinoma and Hürthle cell carcinoma. Our aim was to evaluate how extent of invasion impacts clinical outcome for PDTC. Methods: We retrospectively identified 47 consecutively diagnosed cases of PDTC that were resected between 2005 and 2018. All cases were reviewed to confirm that the tumors met the 2017 Endocrine WHO criteria of PDTC. In addition, tumors were categorized as follows: encapsulated with capsular penetration only, encapsulated with focal vascular invasion (fewer than four foci), encapsulated with extensive vascular invasion (four or more foci), or widely invasive. Histopathologic characteristics and clinical outcome data were recorded. Results: A total of 47 cases of PDTC, including 15 oncocytic tumors, were identified from 28 (60%) women and 19 (40%) men (mean age of 57 years at diagnosis). The mean tumor size was 4.3 cm. Mitoses numbered 8 per 10 high-power fields (HPF) on average (range: 1-34), and necrosis was present in 21 (45%) cases. Eight (17%) cases were encapsulated with capsular penetration only, 5 (11%) were encapsulated with focal vascular invasion, 18 (38%) were encapsulated with extensive vascular invasion, and 16 (34%) were widely invasive. Of the 42 (89%) patients with follow-up data, 7 (17%) died of disease (with a mean survival time of 6.4 years), 11 (26%) have distant metastatic disease, and 24 (57%) have no evidence of disease (mean follow-up 5.6 years). Eight (19%) patients presented with M1 disease at diagnosis. The 5-year disease-free survival (DFS) for patients with M0 disease at diagnosis was 100% for patients with tumors with capsular invasion only or focal vascular invasion (n = 7), 73% for patients with encapsulated tumors with extensive vascular invasion (n = 11), and 17% for patients with widely invasive PDTCs (n = 6). DFS estimates by Kaplan-Meier analysis were significantly different between these groups (p = 0.0016). Conclusions: Extent of invasion appears to be an important parameter that affects clinical outcome for patients with PDTC. In our cohort, patients with encapsulated PDTC with capsular invasion only or focal vascular invasion had an excellent outcome.
引用
- Wong KS, Lorch JH, Alexander EK, et al. Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. Thyroid. 2019. PMID: 31397224. doi:10.1089/thy.2019.0263
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。